Fig. 3From: LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trialPrevalence of patients who are overweight, obesity grade I, obesity grade II and obesity grade III* and with abdominal obesity. *The sum of the prevalence of patients in BMI obesity grades equal 100 %. ATPIII, adult treatment panel III criteria; BMI, body mass index; IISHMS, International Joint Interim Statement for the Harmonization of the Metabolic Syndrome criteria; WC, waist circumferenceBack to article page